 |
|
Randomized Placebo-Controlled Trial of Metformin for Adolescents With Polycystic Ovary Syndrome
Tracey Bridger, MD, FRCPC;
Suzanne MacDonald, MD, FRCPC;
Franziska Baltzer, MD, FRCPC;
Celia Rodd, MD, FRCPC
Arch Pediatr Adolesc Med. 2006;160:241-246.
Objective To determine whether metformin or placebo could, in conjunction with healthy lifestyle counseling, decrease serum testosterone levels and related aberrations in adolescents with hyperandrogenism, hyperinsulinemia, and polycystic ovarian syndrome.
Design Randomized, placebo-controlled, double-blind trial.
Setting Pediatric university teaching hospital.
Participants Twenty-two adolescents aged 13 to 18 years with hyperinsulinemia and polycystic ovarian syndrome.
Intervention Participants were randomly assigned to take a 12-week course of either metformin or placebo.
Main Outcome Measures Pretreatment and posttreatment oral glucose tolerance tests, fasting lipid profiles, and clinical measurements.
Results There was a significant decline in mean serum testosterone concentration with metformin (–38.3 ng/dL) compared with placebo (–0.86 ng/dL) (95% confidence interval, – to –0.29 for the mean difference between groups). At completion, the relative risk of menses was 2.50 times higher in the metformin group compared with the placebo (95% confidence interval, 1.12 to 5.58). Measures of insulin sensitivity, including insulin area under the curve and HOMA (homeostasis model assessment), demonstrated improvement only with metformin, but these did not reach statistical significance. High-density lipoprotein cholesterol levels increased by 6.98 mg/dL with metformin vs a decrease of –2.33 mg/dL with placebo (95% confidence interval, 0.78 to 18.23 for the mean difference between groups). There were no significant changes in body mass index, hirsutism, triglyceride levels, or total and low-density lipoprotein cholesterol levels.
Conclusion Metformin significantly lowered total testosterone concentrations, increased the likelihood of menses, and improved high-density lipoprotein cholesterol levels without affecting measures of insulin sensitivity or body weight.
Author Affiliations: Department of Pediatrics, Memorial University of Newfoundland, St John's (Dr Bridger); Department of Pediatrics, McGill University, Montreal, Quebec (Drs MacDonald, Baltzer, and Rodd).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Impact of Metformin, Oral Contraceptives, and Lifestyle Modification on Polycystic Ovary Syndrome in Obese Adolescent Women: Do We Need a New Drug?
Legro
J. Clin. Endocrinol. Metab. 2008;93:4218-4220.
FULL TEXT
POSITION STATEMENT: Glucose Intolerance in Polycystic Ovary Syndrome A Position Statement of the Androgen Excess Society
Salley et al.
J. Clin. Endocrinol. Metab. 2007;92:4546-4556.
ABSTRACT
| FULL TEXT
Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial
Trolle et al.
Hum Reprod 2007;22:2967-2973.
ABSTRACT
| FULL TEXT
A 27-Year-Old Woman With a Diagnosis of Polycystic Ovary Syndrome
Legro
JAMA 2007;297:509-519.
ABSTRACT
| FULL TEXT
Pharmacotherapy of Childhood Obesity: An evidence-based, conceptual approach
Freemark
Diabetes Care 2007;30:395-402.
FULL TEXT
An adolescent with polycystic ovary syndrome
Ojaniemi and Pugeat
Eur J Endocrinol 2006;155:S149-S152.
ABSTRACT
| FULL TEXT
Adolescent Polycystic Ovary Syndrome: Randomized Study of Metformin
Varma
AAP Grand Rounds 2006;16:81-82.
FULL TEXT
Metformin: An Option for Adolescents with Polycystic Ovary Syndrome
JWatch Pediatrics 2006;2006:8-8.
FULL TEXT
|
